The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; OncoC4; Turnstone Bio
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Turnstone Bio; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Roche; Sellas Life Sciences; Turnstone Bio; Turnstone Bio; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Moderna Therapeutics; Novartis; Roche
 
Muhammad Adnan Khattak
Honoraria - Evaxion Biotech
Consulting or Advisory Role - Moderna Therapeutics
Travel, Accommodations, Expenses - Evaxion Biotech; Moderna Therapeutics; Pierre Fabre
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Tarek Meniawy
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Regeneron; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; OncoSec; Regeneron; Roche
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Exelixis; Merck
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
George Ansstas
No Relationships to Disclose
 
Kevin B. Kim
Stock and Other Ownership Interests - Arvinas; Cryoport; Cryoport (I)
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Sanofi/Regeneron; Sanofi/Regeneron
Speakers' Bureau - Bristol Myers Squibb Foundation; Sanofi/Regeneron
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Regeneron (Inst); Summit pharmaceuticals (Inst)
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Ryan J. Sullivan
Consulting or Advisory Role - Bristol-Myers Squibb; maren; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Mark B Faries
Consulting or Advisory Role - Bristol-Myers Squibb; Instil Bio; Merck; Novartis; Regeneron
 
Thuy Tran
No Relationships to Disclose
 
Charles Lance Cowey
Employment - Texas Oncology; US Oncology
Leadership - US Oncology
Consulting or Advisory Role - Iovance Biotherapeutics
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst)
 
Theresa Medina
Research Funding - Agenus (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Day One Biopharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); InflaRx (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst); Xencor (Inst)
 
Jennifer Margaret Segar
No Relationships to Disclose
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Provectus Biopharmaceuticals; QBiotics
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; QBiotics
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Expert Testimony - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; OncoSec; Pierre Fabre
 
Geoffrey Thomas Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exicure; Genentech; HUYA Bioscience International; Iovance Biotherapeutics; Lyell Immunopharma; Merck; Novartis; Regeneron; Sapience Therapeutics
Research Funding - Exelixis (Inst); Lucerno Dynamics (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Takeda (I)
Consulting or Advisory Role - Instil Bio; Iovance Biotherapeutics; Merck; Nektar; Novartis; Pfizer; Sanofi; Werewolf Pharma; Xilio Therapeutics
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Robert S. Meehan
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics